Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Keythera (Suzhou) Pharmaceuticals Co. Ltd. operates in the Biotechnology & Pharmaceuticals technology area and has 1 pending office action. The prosecution of this portfolio is handled by 1 distinct examiner and 1 distinct art unit. This reflects a concentrated effort on a specific patent application or set of claims.
The busiest examiner for this portfolio is MCMILLIAN, KARA RENITA, who holds 1 pending office action. This action represents the entirety of the 1 pending office action for the company. The presence of the distinct art unit suggests that the technical subject matter is highly unified within the pharmaceutical field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCMILLIAN, KARA RENITA | 1 | 30.7% | +37.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17413262 | MACROCYCLIC COMPOUND AS CDK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | MCMILLIAN, KARA RENITA | 352d overdue |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17413262 | MACROCYCLIC COMPOUND AS CDK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | MCMILLIAN, KARA RENITA | 1623 | §103 | Non-Final OA | 352d overdue | Pending | Jun 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial